Calculated
DCF
Free cash flow, growth, discount rate, and terminal growth form an intrinsic value range.
177.80 USD166.18 USD208.37 USD
+122%
166.18 USDCurrent price is 121.7% above the base model value.
E
US
ELV.US · Elevance Health, Inc.
US · US
Latest price368.48 USD
30D+14.32%
Vs. base value+15.2%
Research summary
ELV.US latest organized financial period shows revenue grew +12.49% YoY and net income declined -5.32% YoY. Current price is about 368 USD, while the model base case is about 320 USD; the current price sits +15.2% versus the base case. The page shows both reported and adjusted views; valuation still defaults to reported figures, while adjusted figures help isolate structured one-time-item impact. This summary is intended for public-information research and model review.
Key financial trend
Annual financial metrics with switchable views. · Unit: USD
Revenue199B USD
Net income6B USD
Free cash flow3B USD
Operating cash flow4B USD
Price trend
Price date: 2026/04/29 · Updated: 2026/04/29 15:27
Valuation model range
Hover each model row to inspect formulas and inputs.
Current price368.48 USD
Base value319.92 USD
Vs. base+15.2%
Price date2026/04/29
319.92 USD319.92 USD319.92 USD
+15.18%
Calculated
Owner Earnings
Uses recent net income as an owner-earnings proxy and discounts scenario growth.
348.39 USD341.01 USD385.77 USD
+8.06%
341.01 USDCurrent price is close to the base model value.Adjusted reference: 341.49 USD
Calculated
Reverse DCF
Solves the forward FCF growth rate implied by the current price.
Implied growth8.5%
Current price implies roughly 8.5% annualized FCF growth.
8.5%Current price implies roughly 8.5% annualized FCF growth.
Calculated
Earnings Power Value
Estimates earnings power value without assuming growth.
306.93 USD306.93 USD306.93 USD
+20.05%
306.93 USDCurrent price is 20.1% above the base model value.
Updated: 2026/04/29 15:27
Valuation basis and non-recurring items
Collapsed by default. Expand to inspect structured one-time items and adjusted figures without making them the primary page focus.
ExpandCollapse
Valuation basis and non-recurring items
Collapsed by default. Expand to inspect structured one-time items and adjusted figures without making them the primary page focus.
A positive amountAfterTax means the item increased reported net income; a negative value means it reduced reported net income. Adjusted net income = reported net income minus total after-tax impact. Valuation defaults to reported figures; adjusted figures are shown to observe one-time-item impact.
| Period | Item | Category | After-tax impact | Confidence |
|---|---|---|---|---|
| 2025/12/31 | Asset impairment | Impairment | -85M USD | Medium |
| 2024/12/31 | Asset impairment | Impairment | -163M USD | Medium |
| 2024/12/31 | Business sale gain/loss | Asset sale gain/loss | 318M USD | Medium |
| 2023/12/31 | Asset impairment | Impairment | -1B USD | Medium |
| 2022/12/31 | Asset impairment | Impairment | -11M USD | Medium |
| 2021/12/31 | Other special charges | Other | -17M USD | Medium |
| 2026/03/31 | Asset impairment | Impairment | -3M USD | Medium |
| 2025/09/30 | Asset impairment | Impairment | -55M USD | Medium |
| 2024/09/30 | Asset impairment | Impairment | -163M USD | Medium |
| 2024/09/30 | Business sale gain/loss | Asset sale gain/loss | 256M USD | Medium |
| 2024/06/30 | Business sale gain/loss | Asset sale gain/loss | 758M USD | Medium |
Ad placement
Quarterly and annual financial table
Financial DetailsShowing latest 5 / 13
| Period | Type | Revenue | Net Income | Adjusted net income | Free Cash Flow | Diluted EPS | Adjusted EPS |
|---|---|---|---|---|---|---|---|
| 2025/12/31 | Annual | 199B USD | 6B USD | 6B USD | 3B USD | 25.21 | 25.59 |
| 2024/12/31 | Annual | 177B USD | 6B USD | 6B USD | 5B USD | 25.68 | 25.02 |
| 2023/12/31 | Annual | 171B USD | 6B USD | 7B USD | 7B USD | 25.22 | 29.67 |
| 2022/12/31 | Annual | 157B USD | 6B USD | 6B USD | 7B USD | 24.81 | 24.86 |
| 2021/12/31 | Annual | - | - | - | - | - | - |
Ad placement